| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 114001 | 25 tests | $150 | ||
| 114002 | 100 tests | $310 |
| Clone | Belantamab |
|---|---|
| Application | Flow Cytometry |
| Reactivity | Human |
| Format | iF647 |
| Target Name | BCMA, BCM, TNFRSF17, CD269 |
| Isotype | Human IgG1 |
| Antibody Type | Monoclonal |
| Regulatory Status | RUO |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA |
| Protein Concentration | Supplied at a lot-specific concentration. |
| Storage&Handling | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Recommended Usage | For flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. |
| Excitation Laser | Red Laser (633 nm) |
| Research Areas | Plasma cells, Cancer Marker, Autoimmunity |
| See All Formats | Clone Belantamab |
Human B-cell maturation antigen (BCMA), also known as CD269 or TNFRSF17, is a cell-surface receptor belonging to the tumor necrosis factor receptor (TNFR) superfamily. Encoded by the TNFRSF17 gene, BCMA is expressed predominantly on mature B cells, plasmablasts, and plasma cells. It plays a crucial role in B-cell maturation, plasma-cell survival, and antibody production by supporting the maintenance of antibody-secreting cells. BCMA signaling contributes to humoral immunity and helps sustain long-lived plasma cells responsible for producing protective antibodies.
BCMA is a type III transmembrane protein characterized by an extracellular domain containing cysteine-rich motifs, a single transmembrane segment, and an intracellular domain involved in signal transduction. Its two principal ligands are B-cell activating factor (BAFF, also known as BLyS) and a proliferation-inducing ligand (APRIL). APRIL generally binds BCMA with high affinity, while BAFF can also interact with BAFF-R and TACI, two other receptors in the TNF receptor family. Ligand binding promotes signaling pathways, including NF-κB activation, that support plasma-cell survival, proliferation, and immunoglobulin production. BCMA can also undergo proteolytic shedding, generating soluble BCMA that may serve as a biomarker of plasma-cell activity and disease burden.
BCMA is particularly important in multiple myeloma, a malignancy of antibody-producing plasma cells. Malignant plasma cells commonly express BCMA, and its signaling can support their survival and persistence within the bone marrow microenvironment. Elevated soluble BCMA levels may correlate with disease burden and treatment response. Because BCMA expression is concentrated on the plasma-cell lineage, it provides a useful target for selectively directing therapies toward malignant plasma cells.
BCMA has become a major target in multiple myeloma treatment. Therapeutic approaches include BCMA-directed chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies that connect BCMA-expressing cells to T cells, and antibody-drug conjugates that deliver cytotoxic agents to malignant plasma cells. These strategies have demonstrated clinical benefit in multiple myeloma, although treatment resistance and adverse effects remain important considerations. Human BCMA is widely used in immunology research, plasma-cell biology, biomarker development, and targeted cancer immunotherapy.
iF647 Human IgG1 Isotype Control Antibody
iF647 Anti-human CD269 (BCMA) Antibody TDS
Have a product or application question? Consult our FAQs or contact us.
